Similar challenges have been observed with other CAR-T therapies targeting different antigens, such as CD19, CD20, and ALK. This suggests that second-generation CAR-T cells struggle against cancer ...

one from the CD19 protein that allows detection by any anti-CD19 CAR T cell; and an anti-CD20 antibody fragment. Together these domains comprise the mechanism of action of ALETA-001, binding to ...

Poseida will carry out development work on the BCMA and CD19/CD20 CAR-Ts through to the end of the phase 1 dose-escalation stage, with the work largely funded by Roche, according to an SEC filing.

Lyell Immunopharma (LYEL) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy, RMAT, ...

CAR-T Target Luciferase Reporter Cells can be used as a target cancer cell for in vitro killing assay by CD19, CD20, or HER2 CAR-T cells. These luciferase expressing cell lines were derived from ...

Roche has since nominated a CD19/CD20 programme and added a third against an undisclosed dual target last month, sparking a $16 million payment to Poseida. Roche's bid to take full control also ...

Consider that with other therapies like CD19 inhibitors or CD20 inhibitors, it can take a patient 6 months or more to see recovery of B-cells. However, with obexelimab, it is believed that B-cells ...

Lyell Immunopharma’s (LYEL) jumped over 8% on Friday as investors’ interest surged. Despite posting unimpressive Q4 results a week earlier, the ...